Skip to main content

Table 1 Patient characteristics—3rd line treatment

From: Survival in advanced GIST has improved over time and correlates with increased access to post-imatinib tyrosine kinase inhibitors: results from Life Raft Group Registry

Year started 3rd line 2002–2006 2007–2012 2013+ Total
Number of patients 73 198 73 344
Alive 3 (4.1%) 27 (13.6%) 48 (65.8%) 78 (22.7%)
Dead 70 (95.9%) 171 (86.4%) 25 (34.2%) 266 (77.3%)
Had regorafenib at any time 2 (2.7%) 48 (24.2%) 61 (83.6%) 111 (32.3%)
Female 31 (42.5%) 77 (38.9%) 39 (53.4%) 147 (42.7%)
Male 42 (57.5%) 121 (61.1%) 34 (46.6%) 197 (57.3%)
Median age/range at start of treatment (3L) 54.0 (18–90) 58.2 (18–88) 60.8 (19–84) 57.8 (18–90)
Age at diagnosis
 < 18 3 (4.1%) 3 (1.5%) 2 (2.7%) 8 (2.3%)
 ≥ 18–35 9 (12.3%) 21 (10.6%) 6 (8.2%) 36 (10.5%)
 ≥ 35 60 (82.2%) 174 (87.9%) 65 (89.0%) 299 (86.9%)
 Unknown 1 (1.4%)  
Last reported treatment line
 3L 35 (47.9%) 57 (28.8%) 39 (53.4%) 131 (38.1%)
 4L 14 (19.2%) 37 (18.7%) 17 (23.3%) 68 (19.8%)
 5L 11 (15.1%) 32 (16.2%) 9 (12.3%) 52 (15.1%)
 6L 6 (8.2%) 32 (16.2%) 3 (4.1%) 41 (11.9%)
 7L 5 (6.8%) 19 (9.6%) 4 (5.8%) 28 (8.1%)
 8L 0 6 (3.0%) 0 6 (11.9%)
 9L 2 (2.7%) 8 (4.0%) 1 (1.4%) 11 (3.2%)
 10L 0 1 (0.5%) 0 1 (0.3%)
 11L 0 3 (1.5%) 0 3 (0.9%)
 12L 0 2 (1.0%) 0 2 (0.6%)
 13L 0 1 (0.5%) 0 1 (0.3%)
Mutations/% (known mutations)
 KIT 15 (78.9%) 95 (75.4%) 40 (75.5%) 150 (75.8%)
  Exon 11 10(52.5%) 64 (50.8%) 31 (58.5%) 105 (53.0%)
  Exon 9 5 (26.3%) 25 (19.8%) 7 (13.2%) 37 (18.7%)
  Exon 13 4 (3.2%) 1 (1.9%) 5 (2.5%)
  Exon 17 1 (0.8%) 1 (1.9%) 2 (1.0%)
 PDGFRA 1 (5.3%) 7 (5.6% 4 (7.5%) 12 (6.1%)
  Exon 12   1 (0.8%) 1 (0.5%)
  Exon 18–D842V 1 (5.3%) 5 (4.0%) 3 (5.6%) 9 (4.5%)
  Exon 18 non-D842V   1 (0.8%) 1 (1.9%) 2 (1.0%)
Wildtype for KIT/PDGFRA 3 (15.8%) 22 (17.5%) 7 (13.2%) 32 (16.2%)
SDHA   2 (3.8%) 2 (1.0%)
SDHB 2 (1.6%) 2 (1.0%)
Total/% known mutations 19 (26%) 126 (63.6%) 53 (72.6%) 198 (57.6%)
Unknown mutations 54 (74.0%) 72 (36.4%) 20 (27.4%) 146 (42.4%)
Primary tumor location
 Small intestine 32 (43.8%) 85 (42.9%) 34 (46.6) 151 (43.9%
 Stomach 27 (37.0%) 81 (40.9%) 29 (39.7%) 137 (39.8%)
 Unknown 7 (9.6%) 10 (5.1%) 2 (2.7%) 19 (5.5%)
 Peritoneum 1 (1.4%) 2 (1.0%) 3 (4.1%) 6 (1.7%)
 Omentum 1 (1.4%) 3 (1.5%) 1 (1.4%) 5 (1.5%)
 Mesentery 1 (1.4%) 4 (2.0%) 5 (1.5%)
 Rectum/anus 1 (1.4%) 3 (1.5%) 1 (1.4%) 5 (1.5%)
 Colon 5 (2.5%) 5 (1.5%)
 Other 3 (4.1%) 5 (2.5%) 3 (4.1%) 11 (3.2%)